Manila Bulletin
PH’s P204-M COVID-19 vaccine ‘mix and match’ trial to be rolled out in Muntinlupa on Nov. 22
The Philippines' P204.19 million clinical trial for mixing and matching different COVID-19 vaccine brands has begun, with the Department of Science and Technology (DOST) overseeing the initiative.
The trial, named 'Mix and Match' (MnM) study, aims to evaluate the safety and immunogenicity of different vaccine platforms in Filipino adults.
The Food and Drug Administration (FDA) approved the clinical trial on November 16.
The trial started in Marikina City on November 19 with three volunteer participants, and is set to roll out in Muntinlupa City on November 22.
Manila City will also conduct its dry run in the same week, with other participating cities including Davao and Dasmariñas in Cavite.
Participants must be at least 18 years old and have not yet been vaccinated against COVID-19.
DOST Undersecretary for Research and Development Dr. Rowena Cristina L. Guevara stated that the largest expense for the trial will be the tests conducted on participants.
The 18-month-long trial is led by Dr. Michelle De Vera of the Philippine Society for Allergy, Asthma, and Immunology (PSAAI).
Topics in this story
Explore more stories about these topics.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
The Philippine FDA approved on Nov. 17 the country's coronavirus disease (COVID-19) vaccine mix-and-match trials.
+1
Read more →
Muntinlupa City has achieved an 86.3% vaccination rate for its target population, with nearly 333,000 residents fully vaccinated against COVID-19 as of November 14.
Read more →